ARS Pharma develops and sells neffy, a nasal spray form of epinephrine for emergency treatment of severe allergic reactions. It last closed at $3.65 on Nov 17, up 1.67% on the day. SPRY last reported earnings on Thu, Aug 13, 2026. The average 12-month price target from 2 analysts is $18.50 (+406.8% from the last close), with a high of $20.00 and a low of $17.00.
Only 2 firms rated SPRY in the past 90 days, not enough for a consensus
Average 12-month target
$18.50
▲ 406.8% upside
Based on 2 analysts who set a price target on SPRY in the past 90 days. The average target is $18.50, with a high of $20.00 and a low of $17.00, compared with the last close of $3.65.
Low $17.00Avg $18.50High $20.00
Blue marker: last close $3.65
Highest target$20.00
Average target$18.50
Lowest target$17.00
Latest rating changes
Cantor FitzgeraldTarget lowered
Nov 6Buy$30 → $20
Raymond JamesDowngrade
Nov 6Buy$17
Leerink PartnersMaintained
Jun 25Buy$24
Cantor FitzgeraldMaintained
May 28Buy$30
Date
Firm
Action
Rating
Price target
Nov 6
Cantor Fitzgerald
Target lowered
Buy
$30 → $20
Nov 6
Raymond James
Downgrade
Buy
$17
Jun 25
Leerink Partners
Maintained
Buy
$24
May 28
Cantor Fitzgerald
Maintained
Buy
$30
Loading…
Technical Analysis
SPRY · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 91% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 49). The nearest support is the 20 day average at $3.55, and the nearest resistance the Pivot R1 at $3.78.
Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 9.3%/day
Key levels
$13.1552 week high+260.3%
$6.97200 day average+91.0%
$5.20100 day average+42.5%
$4.13Swing high (Nov 11)+13.2%
$4.0050 day average+9.6%
$3.78Pivot R1+3.6%
$3.65Pivot+0.0%
$3.65Last close
$3.5520 day average−2.7%
$3.52Pivot S1−3.6%
$2.4452 week low−33.2%
$2.44Swing low (Nov 6)−33.2%
Indicators
RSI (14)
48.51
Middle of its range
Neutral
MACD
-0.14
Above its signal line
Bullish
Stochastic
75.2
Middle of its range
Neutral
ADX (14)
21.7
Weak trend
Williams %R
-28.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
13.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+19.7%
Change over 10 sessions
Bullish
ATR (14)
$0.34
Typical daily range, 9.3% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityHigh, 25.8%/day
Key levels
$13.1552 week high+260.3%
$6.97200 day average+91.0%
$5.20100 day average+42.5%
$4.13Swing high (Nov 11)+13.2%
$4.0050 day average+9.6%
$3.78Pivot R1+3.6%
$3.65Pivot+0.0%
$3.65Last close
$3.5520 day average−2.7%
$3.52Pivot S1−3.6%
$2.4452 week low−33.2%
$2.44Swing low (Nov 6)−33.2%
Indicators
RSI (14)
35.50
Weak, oversold below 30
Neutral
MACD
-1.23
Below its signal line
Bearish
Stochastic
24.2
Middle of its range
Neutral
ADX (14)
36.2
Trending down
Williams %R
-70.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-78.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−23.3%
Change over 10 sessions
Bearish
ATR (14)
$0.94
Typical daily range, 25.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for SPRY
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SPRY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SPRY usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SPRY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRY is in one of them and how their past SPRY trades turned out.
ARS Pharma is a biopharmaceutical company that develops and sells neffy, an epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis. The product is given through the nose without a needle, and it is sold under other trade names in Europe, the U.K. and China. Its customers include patients, caregivers, and the doctors who prescribe it, and partners help commercialize the product in several countries. The company is headquartered in San Diego, California.